NCT06777433 - Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 13, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

June 30, 2026

Conditions

Brain Metastases From Solid Tumors

Interventions

DRUG

RAD101 (18F-FPIA)

A single dose of 18F-RAD101 with a maximum of 370 MBq (10 mCi) administered as a slow IV bolus injection over a maximum of 30 seconds, followed by a saline flush.

Trial Locations (5)

46526

RECRUITING

Goshen Center for Cancer Care, Goshen

48109

RECRUITING

University of Michigan, Ann Arbor

48201

RECRUITING

Karmanos Cancer Institute, Detroit

49503

RECRUITING

BAMF Health, Grand Rapids

60169

RECRUITING

Ascension Illinois Oncology Research, Hoffman Estates